Rheumatology

Biocon Reports Biosimilars Revenue Growth

October 23rd 2020

By Tony Hagen

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.

Biogen, Samsung Report Third-Quarter Biosimilar Results

October 21st 2020

By Tony Hagen

Article

Earnings fell overall for Biogen, although biosimilar revenues continued an upward climb.

NeuClone's Ustekinimab Candidate Shines in Phase 1 Trial

October 20th 2020

By Tony Hagen

Article

Demonstrated biosimilarity across clinical parameters puts this drug among NeuClone's leading product candidates.

CT-P10 and Reference Rituximab Evaluated in Primary Sjögren Syndrome

October 20th 2020

By Deana Ferreri, PhD

Article

Investigators note similar efficacy and safety profiles in real-life study of reference and biosimilar forms of rituximab.

Avalere: Step Therapy May Exacerbate Patient, Payer Costs

October 19th 2020

By Tony Hagen

Article

An Avalere analysis suggests costs are more moderate and lower under a no–step therapy scenario for patients with Crohn disease.

ICER: Infliximab Is Highest in Cost-Effectiveness for UC

October 19th 2020

By Skylar Jeremias

Article

Reviewers found that costs of reference infliximab and its biosimilars make it the most cost-effective therapy for ulcerative colitis (UC) among targeted immune modulators.

Amgen 2020 Biosimilar Report Provides Market Share, ASP Info

October 14th 2020

By Tony Hagen

Article

Amgen's 2020 biosimilar report goes into detail on market share and costs for biosimilars across the therapeutic spectrum in the United States.

PIRG Files Amicus Brief in Support of Humira Plaintiffs

October 13th 2020

By Tony Hagen

Article

The US Public Interest Research Group (PIRG) contends AbbVie's patent thicket for Humira (adalimumab) will encourage anticompetitive practices by other manufacturers.

Promising Results in CD, UC for Celltrion Infliximab Biosimilar

October 12th 2020

By Skylar Jeremias

Article

Celltrion Healthcare reports on progress with higher predose levels of the infliximab biosimilar Remsima in patients with Crohn disease (CD) and ulcerative colitis (UC).

Report: Specialty Drug Assessment Highlights Biosimilar Progress

October 12th 2020

By Skylar Jeremias

Article

Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.